Clinical Trial Update: C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection [Phase 2]

View source ↗

Summary

Phase 2 trial update for C1-Inhibitor (INH) in refractory antibody-mediated rejection after kidney transplant; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection of Kidney Transplant
• Kidney Transplant Rejection

Drugs mentioned

• C1-Inhibitor (INH) (C1-Inhibitor)

Snippet

Sponsor: NYU Langone Health | Conditions: Antibody Mediated Rejection of Kidney Transplant | Phase 2 | Status: COMPLETED | Results posted: 2019-07-11